Schedule 13G ownership disclosure

CIDARA THERAPEUTICS INC

Common Stock, par value $0.0001 per share · CUSIP: 171757206

Event date: 2025-10-15

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • BIOTECHNOLOGY VALUE FUND L P

    Shares: 635,200.00 · Class: 2.3%

  • BVF I GP LLC

    Shares: 635,200.00 · Class: 2.3%

  • BIOTECHNOLOGY VALUE FUND II LP

    Shares: 461,474.00 · Class: 1.7%

  • BVF II GP LLC

    Shares: 461,474.00 · Class: 1.7%

  • Biotechnology Value Trading Fund OS LP

    Shares: 73,866.00 · Class: 0.3%

  • BVF Partners OS Ltd.

    Shares: 73,866.00 · Class: 0.3%

  • BVF GP HOLDINGS LLC

    Shares: 1,096,674.00 · Class: 4.0%

  • BVF PARTNERS L P/IL

    Shares: 1,189,165.00 · Class: 4.4%

  • BVF INC/IL

    Shares: 1,189,165.00 · Class: 4.4%

  • LAMPERT MARK N

    Shares: 1,189,165.00 · Class: 4.4%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000921895-25-002761
Form type
SCHEDULE 13G/A
Filer
BIOTECHNOLOGY VALUE FUND L P
CIK
CIK 918923
Filed
Oct 17, 2025
Reporting period
Oct 15, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub